WEST FRONT STRATEGIES LLC for FRESENIUS KABI USA LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing; issues related to Biosimilars; issues related to competition; issues related to drug shortages; DRUG Act (HR 6283, S. 1542).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
| SHIMON STEIN | — |
Copyright/Patent/Trademark CPT
Issues related to patent policy and reform, including to address patent thickets (HR 6986, S. 3583) and Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220, HR 4370), and Patent Eligibility Restoration Act of 2023 (S. 2140) FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429) Prescription Pricing for the People Act of 2023 (S.113); Preserve Access to Affordable Generics and Biosimilars Act (S.142); Affordable Prescriptions for Patients Act of 2023 (S.150).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
| SHIMON STEIN | — |
Medicare/Medicaid MMM
Formulary placement of generics and biosimilar biological products in Part D; issues related to access to biosimilar biological products in Medicare Part B; issues related to rebate walls.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.